SUMMARY Combinations of antiarrhythmic drugs are frequently used to treat refractory ventricular tachycardia (VT), but few scientific data support this practice. We examined the efficacy and electrophysiology of 110 antiarrhythmic drug combination trials at electrophysiologic study in 74 patients with recurrent ventricular tachycardia. Lidocaine was combined with quinidine in 33 trials, procainamide in 22 and encainide in 20. Propranolol was combined with quinidine in 17 trials, procainamide in 12 and encainide in six. All individual drugs tested (except propranolol, which was usually not tested individually) had failed at electrophysiologic study or clinically in the presence of usually accepted plasma concentrations. Lidocaine in combination with quinidine was effective in 3% of the trials, with procainamide in 5% and with encainide in none of the trials. Propranolol in combination with quinidine was effective in 18% of the trials, with procainamide in 17% and with encainide in none of the trials. The electrophysiologic effects of the tested drug combinations were dominated by the individual effects of the type 1 antiarrhythmic agents. We conclude that the tested antiarrhythmic drug combinations are infrequently effective in preventing VT induction at electrophysiologic study when each agent has failed individually. The addition of lidocaine or propranolol to quinidine, procainamide or encainide does not produce significant synergistic or new effects on the electrophysiologic variables analyzed.
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COMBINATIONS of antiarrhythmic drugs are frequently used for acute and chronic treatment of refractory ventricular arrhythmias. These combinations usually consist of drugs that are ineffective when used individually. Use of combinations of individually ineffective drugs is based on the hypothesis that there may be additive, synergistic or new effects that exceed those of each drug used alone. The use of combinations of antiarrhythmic drugs for refractory arrhythmias has been recommended in several reports. A4 Clinical efficacy in small groups of patients has been demonstrated.5-" Most authorities do not recommend drug combinations as first-line treatment, and usually insist that conventional antiarrhythmic agents in adequate doses must have failed first. Addition of a second drug may antagonize a useful electrophysiologic action of the first drug, and may at the same time have fully additive toxic effects.3 The efficacy of antiarrhythmic drug combinations is poorly documented, especially in the treatment of ventricular arrhythmias.2 Ventricular tachycardia (VT) induction at electrophysiologic study in patients with symptomatic recurrent episodes of VT provides a means of rapid, objective evaluation of acute drug efficacy--2 In this study, we systematically analyzed the efficacy and electrophys-iology of several drug combinations commonly used in the treatment of VT, using prevention of VT induction at electrophysiologic study as an indicator of drug efficacy.
Methods Patients
We retrospectively analyzed all patients with recurrent VT studied in our electrophysiology laboratory. Patients were included in this study if they satisfied the following criteria: (1) Clinically recurrent VT. (2) The diagnosis of VT was confirmed at electrophysiologic study. (3) VT could be induced reproducibly in the absence of antiarrhythmic drugs. (4) Lidocaine was tested in combination with either quinidine, procainamide, or encainide, and each drug (including lidocaine) had failed individually at electrophysiologic study. Lidocaine was not tested individually at electrophysiologic study in 18 of 48 patients. All 18 patients had failed lidocaine clinically in the presence of usually accepted plasma levels. (5) Propranolol was tested in combination with either quinidine, procainamide, or encainide when each of these type 1 agents had failed at electrophysiologic study.
Because of the sequence of drug testing in our laboratory, propranolol was usually tested at the same electrophysiologic study at which another drug had failed, and thus was rarely tested alone.'2 Thus, propranolol was generally tested in combination with other drugs and efficacy of propranolol alone was not usually determined. (9) 198 ± 39 (11) * Combinations with propranolol Quinidine 572 163 (13) 1600±283 (4) 3.4±2.5
Procainamide 1017 191 (6) 3438±515 (6) 
Results

Plasma Levels of Antiarrhythmic Drugs
The mean plasma level of lidocaine at the conclusion of electrophysiologic testing of lidocaine in combination with quinidine was 3.5 + 1.7 ,ug/ml, with procainamide 3.4 ± 1.3 /-tg/ml and with encainide 3.7 + 0.8 ug/ml. Plasma levels of quinidine and procainamide at the conclusion of electrophysiologic testing of combinations of these drugs with lidocaine or propranolol are shown in table 1. Table 2 is a summary of acute efficacy at electrophysiologic study of the tested drug combinations. The combination of lidocaine with quinidine, procainamide or encainide was effective in only two patients.
Efficacy
Oral tocainide was substituted for lidocaine in these combinations, but proved ineffective at a subsequent The individual actions of tested drugs are summarized in figure 1 . Compared with control (off-drug) measurements, lidocaine produced a decrease in sinus cycle length, minor increases in QRS duration and corrected QT, a small decrease in AH interval, a small rise in mean arterial pressure, prolongation of VT cycle length, and an increase in VT induction index (all p < 0.05). Quinidine produced a decrease in sinus cycle length, an increase in QRS duration, a decrease in AH interval, prolongation of the HV interval, a decrease in mean arterial pressure, and an increase in VERP (all p < 0.05). Procainamide produced effects similar to but less marked than those of quinidine. Encainide produced a prolongation of PR interval, QRS duration, corrected QT interval, AH interval and HV interval, a small increase in mean arterial pressure, and prolongation of VT cycle length (p < 0.05).
One would anticipate fewer morphologies of VT and a lower incidence of cardioversion after drug administration, since only one episode of VT induction was necessary to confirm drug failure, while in predrug testing induction of at least three episodes of VT was required. Although only one episode of VT was induced after drug administration, multiple morphologies were frequently induced by attempts at pace termination. These morphologies were included in analysis. The incidence of multiple morphologies of VT was significantly lower only after lidocaine: 15% vs 40% before drug (p < 0.01). Similarly, need for cardioversion to terminate VT was reduced only after quinidine: 9% vs 36% before drug. No statistically significant changes occurred in the number of morphologies of VT or need for cardioversion after administration of the other antiarrhythmic drugs.
Combinations
The combination of lidocaine with quinidine, procainamide or encainide produced very few changes compared with the effects of the latter drugs alone. Addition of lidocaine to quinidine produced a 4- 
Discussion
We found remarkably low efficacy rates for lidocaine in combination with quinidine, procainamide or encainide, using prevention of VT induction at electrophysiologic study as the indicator of drug efficacy. The efficacy rates for propranolol combinations were somewhat higher, but most of these patients had not been proven to be unresponsive to propranolol alone. Acute efficacy rates for single drug trials in our laboratory are 13% for lidocaine, 20% for quindine, 19% for procainamide, 9% for encainide, 27% for propranolol, 1 1% for amiodarone, 10% for lorcainide and 12% for other agents. 13 The acute efficacy rates for propranolol cated using combinations of individually effective antiarrhythmic drugs to provide a "failsafe" mechanism; we did not test this concept in our study. The combination of quinidine with propranolol has been evaluated in two canine studies of atrial and ventricular arrhythmias. 16 17 In both studies, the combination had additive effects compared with the individual drugs in protecting against atrial arrhythmias, but not against ventricular arrhythmias. Our results with clinical VT therefore agree with these canine studies.
The limitations of the method of drug efficacy that we used in this study should be considered. Acute drug efficacy at electrophysiologic study correlates well with long-term antiarrhythmic drug efficacy in patients with VT. 12 However, electrophysiologic study may not predict long-term drug inefficacy as accurately. Mason and Winkle'2 reported a 33% efficacy rate after 6 months and an 11% efficacy rate after 18 months of follow-up in patients treated with drugs predicted to be ineffective at electrophysiologic study. Amiodarone is frequently effective in the long term, although it does not suppress VT induction with acute drug testing. '8 Thus, potentially effective drugs may be discarded on the basis of electrophysiologic study in some patients. Nevertheless, electrophysiologic study provides a systematic, objective means of assessing drug efficacy over a short time in controlled circumstances in patients with potentially lethal arrhythmias. Plasma levels during acute drug testing in this study were in the usually accepted range; use of higher doses may have led to an increased incidence of drug success. Greenspan and colleagues'9 demonstrated an increased success rate with higher-than-normal doses of procainamide. Furthermore, chronic oral antiarrhythmic therapy may be more effective than acute i.v.testing because of accumulation of electrophysiologically active metabolites, or suppression of ectopic beats that trigger the sustained arrhythmia. These limitations must be considered when translating our data to clinical management. 31 The QTc was prolonged in excess of an increase in QRS duration, and the AH interval was lengthened. These changes have been described in patients receiving oral encainide and are probably metabolite effects.4"42 Twelve of our 22 patients were tested on oral encainide.
The electrophysiologic effects of the tested drug combinations were dominated by the individual effects of quinidine, procainamide or encainide, with minor additional effects due to the added drug. For lidocaine combinations, VT cycle length was the most consistently affected electrophysiologic variable. The greatest number of additional effects of lidocaine occurred in combination with encainide (prolonged QRS duration, VERP and VT cycle length). Addition of propranolol to quinidine, procainamide or encainide slowed sinus cycle length and prolonged PR interval, but produced no other significant changes. These findings argue against the presence of major additive (or antagonist) electrophysiologic effects in ventricular tissues due to the drug combinations. Dreifus et al. 43 studied the effects of drug combinations in the isolated rabbit heart and found that the addition of lidocaine to procainamide reduced the rate of phase 0 depolarization. Addition of propranolol to quinidine also caused further decrease in the rate of phase 0 depolarization and prolongation of action potential duration.43 Hondeghem and Katzung found the combination of lidocaine with quinidine to cause further depression of phase 0 depolarization of premature extrasystoles in guinea pig papillary muscles, but noted no other additive effects. 36 Our study suggests that any additive effects of drug combinations at therapeutic plasma concentrations do not cause major electrophysiologic changes in ventricular tissues in man, at least in terms of the variables examined in this study. The combination of lidocaine with encainide may be a possible exception, and further study of this interaction is required.
Clinical Implications
The six antiarrhythmic drug combinations tested in this study were rarely effective in preventing VT induction at electrophysiologic study when each drug had failed individually. If other studies confirm that drug combinations are rarely successful when each drug has failed individually, a reappraisal of serial testing of drug combinations would be in order. A mathematically large number of drug combinations could be tested, side effects are often additive without necessarily increasing antiarrhythmic potency, and the yield in return for patient discomfort and physician time may be poor. A more rational approach is systematic testing of individual drugs in maximal tolerated doses, followed by consideration of alternative forms of treatment, such as mapping-directed arrhythmia surgery, antitachycardia pacemakers, or implantable defibrillators. Exhaustive testing of drug combinations might best be reserved for patients who are poor candidates for nonpharmacologic treatment.
